WO2010123563A3 - Dispositif d'administration à libération contrôlée - Google Patents

Dispositif d'administration à libération contrôlée Download PDF

Info

Publication number
WO2010123563A3
WO2010123563A3 PCT/US2010/001191 US2010001191W WO2010123563A3 WO 2010123563 A3 WO2010123563 A3 WO 2010123563A3 US 2010001191 W US2010001191 W US 2010001191W WO 2010123563 A3 WO2010123563 A3 WO 2010123563A3
Authority
WO
WIPO (PCT)
Prior art keywords
dispensing device
controlled release
release dispensing
therapeutic agent
microparticle
Prior art date
Application number
PCT/US2010/001191
Other languages
English (en)
Other versions
WO2010123563A2 (fr
Inventor
Libin Barry
Jeffrey M. Liebmann
Weiliam Chen
Original Assignee
Sustained Nano Systems Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/386,853 external-priority patent/US8071119B2/en
Priority claimed from US12/592,536 external-priority patent/US20100173000A1/en
Application filed by Sustained Nano Systems Llc filed Critical Sustained Nano Systems Llc
Priority to JP2012507215A priority Critical patent/JP2012524779A/ja
Priority to CA2759807A priority patent/CA2759807C/fr
Priority to EP10767428.5A priority patent/EP2421517A4/fr
Publication of WO2010123563A2 publication Critical patent/WO2010123563A2/fr
Publication of WO2010123563A3 publication Critical patent/WO2010123563A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A61K9/204—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M35/00—Devices for applying media, e.g. remedies, on the human body

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention porte sur un dispositif d'administration ayant un polymère qui est combiné à un agent thérapeutique sous la forme d'une microparticule ou d'une nanoparticule qui est « hypercomprimée » pour former un dispositif d'administration à libération contrôlée et sur des procédés d'administration locale d'un agent thérapeutique à l'aide desdites microparticules.
PCT/US2010/001191 2009-04-23 2010-04-21 Dispositif d'administration à libération contrôlée WO2010123563A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2012507215A JP2012524779A (ja) 2009-04-23 2010-04-21 制御放出分配デバイス
CA2759807A CA2759807C (fr) 2009-04-23 2010-04-21 Dispositif d'administration a liberation controlee
EP10767428.5A EP2421517A4 (fr) 2009-04-23 2010-04-21 Dispositif d'administration à libération contrôlée

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US21445209P 2009-04-23 2009-04-23
US12/386,853 US8071119B2 (en) 2007-05-14 2009-04-23 Controlled release implantable dispensing device and method
US12/386,853 2009-04-23
US61/214,452 2009-04-23
US12/592,536 US20100173000A1 (en) 2007-05-14 2009-11-25 Controlled release implantable dispensing device and method
US12/592,536 2009-11-25

Publications (2)

Publication Number Publication Date
WO2010123563A2 WO2010123563A2 (fr) 2010-10-28
WO2010123563A3 true WO2010123563A3 (fr) 2011-03-17

Family

ID=43011665

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/001191 WO2010123563A2 (fr) 2009-04-23 2010-04-21 Dispositif d'administration à libération contrôlée

Country Status (4)

Country Link
EP (1) EP2421517A4 (fr)
JP (2) JP2012524779A (fr)
CA (1) CA2759807C (fr)
WO (1) WO2010123563A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013020094A2 (fr) * 2011-08-03 2013-02-07 Avant Garde Therapeutics Inc. Nouveau timbre hémostatique et leurs utilisations
JP2020531571A (ja) * 2017-07-11 2020-11-05 サステインドナノシステムズエルエルシーＳｕｓｔａｉｎｅｄ Ｎａｎｏ Ｓｙｓｔｅｍｓ Ｌｌｃ 超圧縮医薬製剤
MX2020000377A (es) * 2017-07-11 2020-07-14 Sustained Nano Systems Llc Esterilizacion mediante radiacion de formas de dosis de polimero hipercomprimido.
BR102020025389A2 (pt) * 2020-12-11 2022-06-21 Edson Luiz Peracchi Implante subcutâneo reabsorvível de longa duração com liberação prolongada de substância farmacologicamente ativa pré-concentrada em polímero para tratamento da dependência a nicotina e processo

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4478818A (en) * 1982-12-27 1984-10-23 Alza Corporation Ocular preparation housing steroid in two different therapeutic forms
WO1999048519A1 (fr) * 1998-03-20 1999-09-30 Takeda Chemical Industries, Ltd. Preparation de polypeptide physiologiquement actif, a liberation prolongee, et production correspondante
US20080292680A1 (en) * 2007-05-14 2008-11-27 Sustained Nano Systems Llc Hypercompressed polymer particles for controlled release ophthalmic medications

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5899411A (ja) * 1981-12-05 1983-06-13 Shoichiro Ozaki 制ガン剤
CH679207A5 (fr) * 1989-07-28 1992-01-15 Debiopharm Sa
US20020111603A1 (en) * 1996-12-02 2002-08-15 Societe De Conseils De Recherches Et D'application Device for local administration of solid or semi-solid formulations and delayed-release formulations for proposal parental administration and preparation process
FR2756493B1 (fr) * 1996-12-02 2001-04-13 Delab Dispositif d'administration locale de formulations solides ou semi-solides
DE19856432A1 (de) * 1998-12-08 2000-06-15 Basf Ag Nanopartikuläre Kern-Schale Systeme sowie deren Verwendung in pharmazeutischen und kosmetischen Zubereitungen
DE10224170A1 (de) * 2002-05-31 2003-12-11 Desitin Arzneimittel Gmbh Pharmazeutische Zusammensetzung mit verzögerter Wirkstofffreisetzung
JP4475891B2 (ja) * 2003-06-20 2010-06-09 ホソカワミクロン株式会社 経肺製剤の製造方法
EP1786400B1 (fr) * 2004-08-12 2009-03-11 Quest Pharmaceutical Services Compositions pharmaceutiques permettant la liberation progressive de composes bioactifs
FR2880273B1 (fr) * 2004-12-30 2007-03-30 Ceva Sante Animale Sa Procede de separation d'une composition pharmaceutique solide a liberation prolongee et controlee sous hautes pressions

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4478818A (en) * 1982-12-27 1984-10-23 Alza Corporation Ocular preparation housing steroid in two different therapeutic forms
WO1999048519A1 (fr) * 1998-03-20 1999-09-30 Takeda Chemical Industries, Ltd. Preparation de polypeptide physiologiquement actif, a liberation prolongee, et production correspondante
US20080292680A1 (en) * 2007-05-14 2008-11-27 Sustained Nano Systems Llc Hypercompressed polymer particles for controlled release ophthalmic medications

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DINARVAND, R. ET AL.: "Preparation of biodegradable mocrospheres and matrix devices containing naltrexone", AAPS PHARMSCI TECH, vol. 4, no. 3, 2003, pages 1 - 10, XP055101164 *
See also references of EP2421517A4 *

Also Published As

Publication number Publication date
JP2012524779A (ja) 2012-10-18
CA2759807A1 (fr) 2010-10-28
CA2759807C (fr) 2018-03-20
JP6250005B2 (ja) 2017-12-20
EP2421517A2 (fr) 2012-02-29
JP2016028066A (ja) 2016-02-25
EP2421517A4 (fr) 2013-08-07
WO2010123563A2 (fr) 2010-10-28

Similar Documents

Publication Publication Date Title
WO2008143906A3 (fr) Particules hypercomprimées pour libération contrôlée de médicaments ophtalmiques
IL221871A (en) Use of a drug containing tetrahydrocannabinol, cannabidiol and tamozolomide for the treatment of glioma
EP2493475A4 (fr) Méthodes et préparations cosmétiques pour la libération prolongée d'agents thérapeutiques dans l'oeil
EP2177210A4 (fr) Procédé de production de microparticules devant être ingérées dans le corps, microparticules devant être ingérées dans le corps et dispersion et composition médicinales les contenant
IL210545A (en) Transplantation devices for use of octreotide transport and use of octreotide to create drugs
EP2019646A4 (fr) Méthode, dispositif et système d'administration de substances thérapeutiques dans l'oeil
WO2013006729A3 (fr) Procédés, compositions et agents de liaison de récepteur cannabinoïde
IL223783B (en) Compound 1-converted indole for use in the treatment of a disease or condition, a pharmaceutical preparation containing the compound and use of the compound to prepare a medicine
WO2010042471A3 (fr) Dispositifs médicaux pour administration d'agents thérapeutiques à des lumières corporelles
HK1159534A1 (en) Methods for ameliorating pain and devices for delivering a medicament
NZ610701A (en) Once daily formulation of lacosamide
WO2008131056A3 (fr) Préparations monoeximiques a libération soutenue d'analgésiques opioïdes et non opioïdes
WO2012054920A3 (fr) Microparticules ciblant des antigènes spécifiques, induisant une tolérance, et leurs utilisations
WO2011028794A3 (fr) Traitement de la chorée de huntington avec de la cyclosérine et un agoniste des récepteurs nmda
EP2237772B8 (fr) Procédé et dispositif multicouche pour la délivrance topique contrôlée d'agents thérapeutiques à la peau
EP4245765A3 (fr) Traitement de troubles metaboliques chez des animaux equins
IL232325A0 (en) 18-methyl-7,6-methylene-3-oxo-17-paragan-4-en-21, 17b-carbolactones, pharmaceutical preparations containing these compounds and their use for the treatment of endometrial disease
MX2010010954A (es) Farmaco contra cancer de higado.
WO2009092129A8 (fr) Composition pharmaceutique de duloxétine à libération retardée
IL206080A0 (en) Pharmaceutical composition for use in the treatment and/or the prevention of osteoarticular diseases
MY173215A (en) Acetylcysteine compositions and methods of use thereof
MX364864B (es) Microesferas o microparticulas biodegradables o bioerosionables de liberacion progresiva suspendidas en una formulacion de farmaco inyectable de formacion de deposito solidificante.
IL199815A (en) Nitric Oxide-releasing steroids and their use in the treatment of ocular diseases through intraocular injection
ZA201102949B (en) Implantable device for the delivery of octreotide and methods of use thereof
WO2014036556A3 (fr) Systèmes d'administration de médicaments et méthodes de traitement du cancer de la prostate

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10767428

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2012507215

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2759807

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2010767428

Country of ref document: EP